Compare Abeona Therapeutics Inc (ABEO) vs Quantumscape Corp (QS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Quantumscape Corp — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Quantumscape Corp trades at $6.52 (market cap $4.18B). The key difference: Quantumscape Corp is far larger — about 11.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | QS | |
|---|---|---|
Market Cap | $373.32M | $4.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $18.44 |
52-Week Low | $4.17 | $5.96 |
Enterprise Value | $228.22M | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QuantumScape trades at $6.79, down 3.96% today, reflecting ongoing investor caution amid its pre-revenue development stage. The stock shows a bearish technical trend with negative cash flows and significant losses, though recent news of a joint research agreement with Honda (June 18, 2026) provides optimism for its solid-state battery technology. Analyst consensus is heavily weighted toward Hold (72.73%) with no Buy ratings, indicating skepticism about near-term commercialization prospects.
The outlook remains high-risk with substantial execution hurdles in battery development and commercialization. While partnerships like Honda offer long-term potential, persistent negative profitability and cash burn pose significant challenges. Investors should weigh the speculative nature against potential disruptive upside in the evolving EV battery market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
